Respiratory insufficiency
Drug research and approvals for respiratory insufficiency: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 319 studies of respiratory insufficiency are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 319
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Automated Oxygen Titration With the EMILY.AI Device During the Six-Minute Walk TestNCT07938086 · Not applicable · Aether Tech S.L. · starts Apr 15, 2026
- Lactate/Albumin Ratio and Mortality in Respiratory FailureNCT07909226 · Not reported · Kocaeli City Hospital · starts Nov 8, 2026
- Respiratory Progression in Adults With Duchenne Muscular Dystrophy.NCT07879989 · Not reported · Istituto Giannina Gaslini · starts Sep 9, 2025
- Role of HFNC During FOB in Patients With Respiratory FailureNCT07880964 · Not applicable · Mansoura University · starts Apr 12, 2026
- Pharyngeal Mucosal Conditioning to Prevent Postoperative Sore Throat in Septoplasty Patients With Severe Nasal…NCT07870252 · Not applicable · Mansoura University · starts Oct 15, 2026
- HFNC Versus NIV in Hypercapneic COPD PatientsNCT07854210 · Not applicable · Mohammed Shehta · starts Nov 3, 2025
- Developing New Ways to Detect Respiratory Impairment Early in ALSNCT07844590 · Not reported · Thomas Jefferson University · starts Sep 1, 2026
- Dynamic Non-invasive Monitoring of Inspiratory EffortNCT07839949 · Not reported · Fundació d'investigació Sanitària de les Illes Balears · starts Aug 4, 2026
- Evaluation of Foreign Body Airway Obstruction Interventions Among Young Children: A Prospective Cohort StudyNCT07817693 · Not reported · University of Calgary · starts May 1, 2026
Approved 1
- Nitric oxideSoluble guanylate cyclase activator
Phase 3 12 of 14
- MidazolamGABA-A receptor; anion channel positive allosteric modulator
- HydroxychloroquineFerriprotoporphyrin IX inhibitor
- DexmedetomidineAdrenergic receptor alpha-2 agonist
- FentanylMu opioid receptor agonist
- Testosterone undecanoateAndrogen Receptor agonist
- Almitrine
- DexamethasoneGlucocorticoid receptor agonist
- TheophyllinePhosphodiesterase 4 inhibitor
- SevofluraneGlycine receptor (alpha-1/beta) positive modulator
- IsofluraneGlycine receptor (alpha-1/beta) positive modulator
- PropofolGABA-A receptor; anion channel positive allosteric modulator
- AzithromycinBacterial 70S ribosome inhibitor
Phase 2 12 of 16
- AlbuterolBeta-2 adrenergic receptor agonist
- MefloquineFerriprotoporphyrin IX inhibitor
- MorphineMu opioid receptor agonist
- RemifentanilMu opioid receptor agonist
- ClopidogrelPurinergic receptor P2Y12 antagonist
- FondaparinuxAntithrombin-III activator
- AlteplaseTissue-type plasminogen activator exogenous protein
- CholecalciferolVitamin D receptor agonist
- TirofibanIntegrin alpha-IIb/beta-3 inhibitor
- AspirinCyclooxygenase inhibitor
- EtomidateGABA-A receptor; anion channel positive modulator
- LucinactantSurfactant agent
Phase 1 or earlier 8
- OxycodoneMu opioid receptor agonist
- SirolimusFK506-binding protein 1A inhibitor
- KetamineGlutamate [NMDA] receptor negative allosteric modulator
- MeropenemBacterial penicillin-binding protein inhibitor
- OxygenEssential for cellular homeostasis
- Dextrose
- Carbon dioxide
- Nitric acid
How its trials ended
1,567 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 311 whose ending is known, 31% met their primary endpoint, 14% missed it and 56% stopped early.
- Completed, result not reported64441%
- Status unknown31520%
- Ongoing29719%
- Met its primary endpoint966%
- Stopped: other or unclear886%
- Stopped: enrollment or feasibility624%
- Missed its primary endpoint423%
- Stopped: lack of efficacy131%
- Stopped: sponsor or business decision6<1%
- Stopped: funding4<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA